Rituximab with interleukin-2 after autologous bone marrow transplantation for acute lymphocytic leukemia in second remission.
Ozsahin
Hulya
H
Fluss
Joël
J
McLin
Valerie
V
Wacker
Pierre
P
Miralbell
Raymond
R
Helg
Claudine
C
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000628:therapy*; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D014182:Transplantation, Autologous
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007376:Interleukin-2; D000069283:Rituximab